EMBLAC Stock Overview
Provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Embla Medical hf. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 29.60 |
| 52 Week High | DKK 0 |
| 52 Week Low | DKK 0 |
| Beta | 0.63 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -38.62% |
| 5 Year Change | -26.64% |
| Change since IPO | 202.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMBLAC | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 5.7% | -1.7% | -1.4% |
| 1Y | n/a | -9.4% | 6.4% |
Return vs Industry: Insufficient data to determine how EMBLAC performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how EMBLAC performed against the UK Market.
Price Volatility
| EMBLAC volatility | |
|---|---|
| EMBLAC Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EMBLAC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EMBLAC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 4,000 | Sveinn Solvason | www.emblamedical.com |
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated.
Embla Medical hf. Fundamentals Summary
| EMBLAC fundamental statistics | |
|---|---|
| Market cap | DKK 12.64b |
| Earnings (TTM) | DKK 395.39m |
| Revenue (TTM) | DKK 5.59b |
32.0x
P/E Ratio2.3x
P/S RatioIs EMBLAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBLAC income statement (TTM) | |
|---|---|
| Revenue | US$804.32m |
| Cost of Revenue | US$310.36m |
| Gross Profit | US$493.96m |
| Other Expenses | US$437.03m |
| Earnings | US$56.93m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 23, 2024
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 61.41% |
| Net Profit Margin | 7.08% |
| Debt/Equity Ratio | 57.4% |
How did EMBLAC perform over the long term?
See historical performance and comparison